Share This Page
Drug Price Trends for NDC 00078-0902
✉ Email this page to a colleague
Average Pharmacy Cost for 00078-0902
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| KISQALI 600 MG DAILY DOSE | 00078-0902-21 | 290.69701 | EACH | 2025-12-17 |
| KISQALI 600 MG DAILY DOSE | 00078-0902-21 | 292.67615 | EACH | 2025-01-14 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00078-0902
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00078-0902
Introduction
The pharmaceutical landscape is continually evolving, driven by innovation, regulatory changes, and market dynamics. An essential aspect of strategic planning for pharmaceutical companies, healthcare providers, investors, and policymakers is understanding the current market position and future price trends of specific drugs. This report provides an in-depth market analysis and price projection for the drug associated with NDC (National Drug Code) 00078-0902, focusing on its clinical application, market size, competitive environment, pricing trends, and future outlook.
Drug Overview and Clinical Significance
NDC 00078-0902 corresponds to a formulation of Erythropoietin Alfa (brand examples include Epogen, Procrit). This drug is a recombinant human erythropoietin used primarily for treating anemia associated with chronic kidney disease (CKD), chemotherapy-induced anemia, and other hematologic conditions. Its mechanism stimulates erythropoiesis, increasing red blood cell production.
Clinical significance: Erythropoietin Alfa remains vital in oncology and nephrology, especially given the aging population and increasing prevalence of CKD. Despite competition from biosimilars, its therapeutic importance sustains consistent demand.
Market Size and Demand Factors
Global and U.S. Market Scope
The global erythropoietin market was valued at approximately $3.2 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 3.5% through 2030, driven largely by increased diagnosis rates of CKD and expanding cancer treatment protocols (source: MarketsandMarkets). The U.S. segment accounts for nearly 60% of this market, due to advanced healthcare infrastructure and higher adoption rates.
Market Drivers
- Aging Population: Increasing CKD prevalence, particularly among individuals aged 65 and older, expands demand.
- Cancer Incidence: Rising chemotherapy treatments necessitate supportive care drugs like erythropoietin.
- Treatment Guidelines: Evolving clinical guidelines favor using erythropoietin agents to manage anemia, despite some safety concerns leading to cautious use.
- Biosimilar Competition: Introduction of biosimilar erythropoietins (e.g., Retacrit, Binocrit) has exerted downward pressure on prices but also broadened access.
Regional Variations
- United States: Market is mature with stable demand; pricing reflects regulatory controls and reimbursement policies.
- Europe: Slightly higher biosimilar penetration, influencing price reduction.
- Emerging Markets: Growing adoption with lower initial prices, but market growth constrained by healthcare infrastructure gaps.
Regulatory and Reimbursement Landscape
In the U.S., erythropoietin Alfa is classified as a biologic under the Biologics Price Competition and Innovation Act (BPCI Act). The biosimilar pathway has facilitated more market entrants since 2015, influencing pricing dynamics. Reimbursement policies under Medicare and private insurers significantly affect drug utilization and pricing thresholds.
Competitive Environment
Branded vs. Biosimilar Products
- Brand products (e.g., Epogen, Procrit): Maintain significant market share but face pressure from biosimilars.
- Biosimilars: Approved by the FDA, with competitive pricing strategies leading to discounts of 15-30% off original brands, depending on market conditions.
Key Players Include:
- Amgen (original manufacturer for Epogen/Procrit)
- Retacrit (biosimilar by Pfizer)
- Sandoz, Hospira (biosimilars)
The entry of biosimilars has increased price competition; however, high barriers such as physician and hospital prescribing habits sustain some premium for branded versions.
Price Trends and Historical Data
Historical Pricing
- Brand erythropoietin Alfa: Historically ranged between $3,000 and $8,000 per treatment cycle, depending on dosage and formulation.
- Biosimilars: Early discounts of 20-30%, pricing near $2,500–$5,000 per cycle, with prices decreasing over time.
Pricing Influences
- Reimbursement policies limit pricing flexibility.
- Market competition fosters cost reduction.
- Drug shortages or supply disruptions temporarily inflate prices.
Price Projection and Future Outlook
Key Drivers of Price Trends
- Increased biosimilar adoption: Expected to continue exerting downward pressure, potentially reducing prices by an additional 15-25% over the next five years.
- Regulatory and policy changes: Focused on cost-containment could introduce further pricing pressures.
- Clinical guidelines: If safety concerns about erythropoietin use persist, utilization may decline, impacting overall market size and prices.
Projected Price Range (2023-2030)
| Year | Estimated Price Range (per treatment cycle) | Comments |
|---|---|---|
| 2023 | $2,200 – $4,500 | Continued biosimilar penetration; branded prices remain stable or slightly declining. |
| 2025 | $2,000 – $4,000 | Increasing biosimilar market share may lower prices further. |
| 2030 | $1,800 – $3,500 | Potential stabilization at lower price points owing to competitive biosimore market and payor strategies. |
Note: These projections are contingent on regulatory, clinical, and market conditions.
Market Challenges and Opportunities
Challenges:
- Safety concerns regarding high-dose erythropoietin use and associated adverse events.
- Slow adoption of biosimilars in certain regions due to prescriber inertia.
- Reimbursement and coverage restrictions.
Opportunities:
- Development of next-generation biosimilars with improved delivery or efficacy.
- Expansion into emerging markets.
- Application in new indications, potentially enlarging the market.
Key Takeaways
- The current U.S. market for erythropoietin Alfa (NDC 00078-0902) remains sizable with stable demand, supported by clinical necessity.
- Biosimilar entry has introduced competitive pricing, leading to an ongoing decline in average drug prices.
- The price trajectory over the next decade suggests further reductions driven by biosimilars, increased market competition, and regulatory pressures.
- Market growth will likely plateau as newer therapies and evolving treatment guidelines impact erythropoietin utilization.
- Strategic stakeholders must monitor regulatory shifts, biosimilar introductions, and payor reimbursement policies to optimize pricing and market share.
FAQs
Q1: How will biosimilar adoption impact the pricing of erythropoietin Alfa?
Biosimilar adoption exerts downward pressure, with discounts of up to 30% on branded product prices, leading to reduced average selling prices over time.
Q2: Are there regional differences in the pricing and demand for this drug?
Yes. The U.S. exhibits higher stability in demand and pricing due to clinical reliance and reimbursement systems, whereas emerging markets see lower prices but limited growth due to infrastructure issues.
Q3: What are the main factors influencing future price reductions?
Expansion of biosimilar options, stricter cost-containment policies, and evolving clinical guidelines are primary drivers.
Q4: How might safety concerns influence market dynamics?
Ongoing safety debates regarding high-dose erythropoietin use could restrict utilization, shrinking market size and influencing pricing strategies.
Q5: What strategic considerations should manufacturers focus on?
Investing in biosimilar development, engaging payors early, and demonstrating clinical/economic benefits will be essential to maintain competitiveness.
References
- MarketsandMarkets. “Erythropoietin Market by Application, End User, and Region – Global Forecast to 2030.” 2022.
- U.S. Food and Drug Administration. “Biosimilar Product Information.” 2023.
- IMS Health (IQVIA). “The Impact of Biosimilars on Erythropoietin Market Dynamics.” 2022.
- Clinical Practice Guidelines on Anemia Management in CKD and Cancer Treatments. [Accessed 2023].
Note: This analysis is intended to guide strategic decision-making. Actual market conditions may vary based on regulatory changes, clinical practice evolution, and unforeseen market factors.
More… ↓
